Gilead, Baxter Ramp Up Lobbying on Trump’s HIV, Kidney Plans

HIV drug manufacturer Gilead Sciences and kidney disease product maker Baxter International found receptive ears at the Department of Health and Human Services in 2019, lobbying records show.

While keeping down prices on costly drugs remained the top talking point for lobbyists, other issues President Donald Trump has recently taken an interest in also appear to be getting increased attention from those with skin in the game.

The Pharmaceutical Research and Manufacturers of America solidly remained the agency’s No. 1 lobbyist to start the year, according to filings analyzed by Bloomberg Law. But Gilead and Baxter both catapulted toward the ...